This NF-κB inhibitory activity of bortezomib has been largely implicated in the clinical efficacy of this drug against MM and another B cell malignancy, Mantle Cell Lymphoma (MCL) [31]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.